Head-to-head evidence
Anti-CD33 CAR T-cells vs Lintuzumab-Ac225
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Acute Myeloid Leukemia
Shared mechanism: CD33 · full Acute Myeloid Leukemia pipeline
Anti-CD33 CAR T-cells
Developed by iCell Gene Therapeutics
NCT01864902 · Phase 1/2 · status unknown
This was a small, single-arm, open-label study with no comparator group, designed primarily to assess safety of this cell therapy in a heavily pretreated leukemia population. Results have not yet been posted.
Next expected readout: September 2028 · NCT05672147 (registry estimate)
Lintuzumab-Ac225
Developed by Actinium Pharmaceuticals
NCT00006045 · Phase 3 · status unknown
This trial tested combination chemotherapy with or without an antibody therapy (lintuzumab) in patients with relapsed or refractory acute myeloid leukemia, but the public registry record does not state whether treatment assignment was randomized or blinded, and no outcome measures or results are available, so its design rigor and findings cannot be established from what is provided.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Anti-CD33 CAR T-cells's landscape · Lintuzumab-Ac225's landscape